Riluzole-induced neutropenia
Riluzole-induced neutropenia
复制标题
利鲁唑诱导的中性粒细胞减少症
DOI：
10.1212/01.wnl.0000123015.48097.9a
复制
发表时间：
2004
期刊：
影响因子：
9.9
通讯作者：
H. Bitterman
中科院分区：
文献类型：
--
作者：
G. Weber;H. Bitterman
1995年，利鲁唑被批准用于治疗ALS，并已成为其标准治疗方法。1该药物的常见副作用为恶心、无力和可逆性肝酶升高。2，3中性粒细胞增多症是一种极其罕见、描述不充分、危及生命的药物不良反应。之前仅报告了一例与利鲁唑剂量意外增加至200 mg/d相关的可逆性中性粒细胞减少症。4对利鲁唑在ALS中的药效学和药代动力学特性进行的审查报告，在4，000例接受该药物的患者中仅报告了3例中性粒细胞减少症，没有任何其他详细信息。5
我们报告一个病人谁开发严重中性粒细胞减少症与标准剂量（100毫克/天）的利鲁唑。
一名71岁的ALS患者因发烧入院。她有动脉高血压和高胆固醇血症病史，22年前因乳腺癌接受了左侧乳房切除术和乳房重建术。她没有接受化疗或放疗。入院前三个月，她被诊断为肌萎缩性侧索硬化症...
The glutamatergic antagonist riluzole was approved in 1995 for the management of ALS and has become its standard therapy.1 Common side effects of the drug are nausea, asthenia, and reversible liver enzyme elevation.2,3⇓ Neutropenia is an extremely rare, not well-described, life-threatening adverse reaction of the drug. Only one case of reversible neutropenia associated with an inadvertent dose increase of riluzole to 200 mg/d has been reported previously.4 A review of the pharmacodynamic and pharmacokinetic properties of riluzole in ALS reported only 3 cases of neutropenia among 4,000 patients who received the drug without any additional details.5
We report a patient who developed severe neutropenia in association with a standard dose (100 mg/d) of riluzole.
A woman aged 71 years with ALS was admitted to the hospital because of fever. She had a medical history of arterial hypertension and hypercholesterolemia and had undergone left mastectomy and breast reconstruction because of breast cancer 22 years earlier. She did not receive chemotherapy or radiotherapy. Three months before her admission, a diagnosis of ALS was …